The Centers for Medicare and Medicaid Services (CMS) announced the selection of 15 high-cost drugs subject to Medicare Part D and, for the first time, Part B, for the third round of the drug price negotiation program.[4] These drugs include Anoro Ellipta, Biktarvy, Botox, Cimzia, Cosentyx, Entyvio, Erleada, Kisqali, Lenvima, Orencia, Rexulti, Trulicity, Verzenio, Xeljanz, and Xolair.[4] Negotiations with the drug manufacturers will take place in 2026 and the agreed prices will come into effect on January 1, 2028.[4] The selection of these 15 drugs represents the highest expenditures from a list of the top 50 drugs eligible for negotiation under combined Medicare Part B and D expenditures.[4] Thus, the Trump administration continues its efforts to reduce drug costs; in the second cycle, all 15 selected drugs were agreed upon with prices effective January 1, 2027, which would save an estimated $8.5 billion in 2024.[4] The program is based on the Inflation Reduction Act, which allows Medicare to directly negotiate the prices of selected drugs without generic or biosimilar competition.[4][5]